Cancer Drug List

20 Apr 2022

Following the Recommendations of the MediShield Life Council on MediShield Life’s Coverage for Outpatient Cancer Drug Treatments, this list shows the outpatient cancer drugs and clinical indications that are claimable under MediShield Life and MediSave and the corresponding limits. It will be implemented in September 2022.

The subsidy classes in the list applies for drugs at public healthcare institutions, and will be implemented by September 2022 or earlier. Drugs can be subsidised under the Standard Drug List (SDL) or Medication Assistance Fund (MAF). More information on drug subsidies and the full list of subsidised drugs can be found here once the subsidy is implemented.

Frequently Asked Questions (FAQs)

Expand All | Collapse All

Does this list also apply to inpatient cancer drug treatments?

No, inpatient cancer drug treatments are covered separately under the inpatient claim limits, together with other costs incurred during the inpatient stay. For example, the MediShield Life claim limit is $1,000 per day for the first two days and $800 per day for the third and subsequent day of normal ward stay, and the MediSave withdrawal limit is $550 for the first two days and $400 for the third and subsequent day of the ward stay.

What is the criteria for inclusion in this list?

Generally, the outpatient cancer drug list comprises drugs that are clinically proven and cost-effective in treating the particular cancer type. A drug is clinically proven if it is registered with the Health Sciences Authority (HSA) for the particular clinical indication and has met the required standards of safety, quality and efficacy. A drug is cost-effective if it provides good value in treating the particular cancer type compared to existing standard of care, in terms of health benefits and cost.

Who assesses the cost-effectiveness of cancer drug treatments?

The Agency for Care Effectiveness (ACE), Singapore’s national HTA agency, assesses the clinical effectiveness and cost-effectiveness of cancer drug treatments using published methodologies that are in line with international best practices. The MOH Oncology Drug Sub-committee (ODS), comprising local clinical experts from the public and private sectors, will be consulted as part of this process. Negotiations are also conducted to ensure that drug manufacturers have opportunities to offer cost-effective prices.

The MOH Drug Advisory Committee (DAC), chaired by the Director of Medical Services in MOH and comprising senior public sector doctors, pharmacists and MOH representatives, reviews ACE’s evaluations, companies’ price proposals and makes recommendations to MOH for subsidy and MediShield Life coverage. This is similarly done for subsidy recommendations for other drugs and vaccines. For the initial outpatient cancer drug list, reference was taken from the DAC’s subsidy recommendations.

More details on the processes and methods can be found on ACE’s website here.

What happens to cancer drug treatments not on the list?

There will not be MediShield Life coverage for cancer drug treatments that are not on the list. As MediShield Life is a basic national insurance scheme, we need to balance between providing better protection for Singaporeans and keeping premiums affordable. Payouts are ultimately funded through premiums. Targeting MediShield Life coverage at clinically proven and cost-effective cancer drug treatments will enable us to stretch the limited pool of premium dollars and support more patients to receive appropriate treatments.

There will not be MediSave coverage for cancer drug treatments that are not on the list as well. MediSave coverage and contribution rates are generally sized to be sufficient for Singaporeans’ basic healthcare needs, which includes large medical expenses such as hospitalisation episodes, recurring outpatient treatments and premiums for national health insurance schemes, especially in old age. Aligning the scope of MediSave coverage to cancer drug treatments on the list ensures that the limited pool of MediSave monies which Singaporeans have saved up over their working lives are used for clinically proven and cost-effective treatments, and that there remains sufficient balances for other healthcare needs. This will help to keep contribution rates reasonable for all Singaporeans.

We encourage patients to discuss carefully with their doctors about the efficacy of treatments that are not on the list, possible side effects and costs, in order to make an informed decision on whether to proceed with the treatment.

How do I apply for a treatment to be included in the list?

You may wish to discuss this with your doctor to raise such a request.

Oncologists can request ACE to evaluate treatments for potential inclusion on the list if there is sufficient clinical evidence to support their use. For example, rare cancers where the treatment is approved by a reputable overseas regulatory authority but not submitted for HSA's approval due to the small patient pool in Singapore.

Cancer Drug List

The subsidy class, and MediShield Life and MediSave limits may change from time to time. The prevailing subsidy class, and MediShield Life and MediSave limits will be applied at the point the patient receives treatment. If more than one cancer drug from the list is used in a month, the patient may claim up to the amounts not exceeding the highest MediShield Life and MediSave claim limits applicable for the individual drugs. For example, if a patient uses both Drugs A (MediShield Life claim limit of $2,000 & MediSave withdrawal limit of $600) and B (MediShield Life claim limit of $1,000 & MediSave withdrawal limit of $600) in a month, the patient may claim no more than $2,000 from MediShield Life and $600 from MediSave in that month.

Click on the column headers to sort. Click Ctrl+F (On Windows) or Cmd+F (On Mac) to look for the specific cancer drug of interest, and check the clinical indication that is covered under MediShield Life and MediSave.

Updated 3 November 2021

Active Ingredient(s)	Dosage Form(s) and Strength(s)	Brand(s)	Clinical Indication	Subsidy Class	MediShield Life Claim Limit per month ($)	MediSave Withdrawal Limit per month ($)
Abemaciclib	Abemaciclib tablet (50 mg, 100 mg, 150 mg)	Verzenio	Abemaciclib in combination with an aromatase inhibitor as initial endocrine-based therapy for HR positive, HER2 negative, advanced or metastatic breast cancer.	MAF	800	600
Abemaciclib	Abemaciclib tablet (50 mg, 100 mg, 150 mg)	Verzenio	Abemaciclib in combination with fulvestrant for treating HR positive, HER2 negative, advanced or metastatic breast cancer in patients who have received prior endocrine therapy.	MAF	800	600
Abiraterone	Abiraterone tablet (250 mg)	-	For cancer treatment.	SDL (Abiranat)	400	600
Acalabrutinib	Acalabrutinib capsule (100 mg)	Calquence	Monotherapy for previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in patients who are unsuitable for fludarabine-based therapy.	MAF	2000	600
Acalabrutinib	Acalabrutinib capsule (100 mg)	Calquence	Acalabrutinib in combination with obinutuzumab for previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in patients who are unsuitable for fludarabine-based therapy.	No subsidy	2000	600
Acalabrutinib	Acalabrutinib capsule (100 mg)	Calquence	Monotherapy for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in patients who have received at least one prior therapy.	MAF	2000	600
Acalabrutinib	Acalabrutinib capsule (100 mg)	Calquence	Treatment of adults with mantle cell lymphoma (MCL) who have received at least one prior therapy.	MAF	2000	600
Afatinib	Afatinib tablet (20 mg, 30 mg, 40 mg)	Giotrif	Treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer.	MAF	600	600
Aflibercept	Aflibercept concentrate for solution for infusion (100 mg/4 mL)	Zaltrap	Aflibercept in combination with FOLFIRI for treating metastatic colorectal cancer that has progressed on first-line systemic therapy.	No subsidy	(Undergoing Evaluation)	(Undergoing Evaluation)
Alectinib	Alectinib capsule (150 mg)	Alecensa	Treatment of locally advanced or metastatic ALK- positive non-small cell lung cancer.	No subsidy	2000	600
Anastrozole	Anastrozole tablet (1 mg)	-	Treatment of hormone receptor positive, postmenopausal women with early and advanced breast cancer.	MAF	200	600
Apalutamide	Apalutamide tablet (60 mg)	Erleada	Treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC).	No subsidy	400	600
Apalutamide	Apalutamide tablet (60 mg)	Erleada	Treatment of adult men with metastatic hormone sensitive prostate cancer (mHSPC).	No subsidy	400	600
Arsenic trioxide	Arsenic trioxide injection (10 mg)	-	For cancer treatment.	No subsidy	3000	600
Atezolizumab	Atezolizumab concentrate for solution for infusion (840 mg/14 mL, 1200 mg/20 mL)	Tecentriq	Atezolizumab in combination with nab-paclitaxel for treating patients with unresectable, locally advanced, or metastatic triple negative breast cancer whose tumours have PDL1 expression >1% and who have not received prior chemotherapy for metastatic disease.	No subsidy	1800	600
Atezolizumab	Atezolizumab concentrate for solution for infusion (840 mg/14 mL, 1200 mg/20 mL)	Tecentriq	Atezolizumab in combination with a platinum agent and etoposide, for previously untreated extensive-stage small cell lung cancer.	No subsidy	1800	600
Atezolizumab	Atezolizumab concentrate for solution for infusion (840 mg/14 mL, 1200 mg/20 mL)	Tecentriq	For previously untreated metastatic non-small cell lung cancer (NSCLC), in patients whose tumours express PD-L1 with a tumour proportion score ≥50%, with no EGFR or ALK genomic tumour aberrations. Treatment with atezolizumab should be stopped at 2 years, or earlier if disease progresses.	No subsidy	1800	600
Atezolizumab	Atezolizumab concentrate for solution for infusion (840 mg/14 mL, 1200 mg/20 mL)	Tecentriq	Treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for metastatic NSCLC. Treatment with atezolizumab should be stopped at 2 years, or earlier if disease progresses.	No subsidy	1800	600
Atezolizumab	Atezolizumab concentrate for solution for infusion (840 mg/14 mL, 1200 mg/20 mL)	Tecentriq	Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin, for the treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who had not received prior chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for metastatic NSCLC. Treatment with atezolizumab should be stopped at 2 years, or earlier if disease progresses.	No subsidy	1800	600
Atezolizumab	Atezolizumab concentrate for solution for infusion (840 mg/14 mL, 1200 mg/20 mL)	Tecentriq	Atezolizumab in combination with nab-paclitaxel and carboplatin, for previously untreated metastatic non-squamous non-small cell lung cancer (NSCLC), in patients with no EGFR or ALK genomic tumour aberrations. Treatment with atezolizumab should be stopped at 2 years, or earlier if disease progresses.	No subsidy	1800	600
Atezolizumab	Atezolizumab concentrate for solution for infusion (840 mg/14 mL, 1200 mg/20 mL)	Tecentriq	Treatment of patients with locally advanced or metastatic urothelial carcinoma whose tumours express PD-L1 (PD-L1 stained tumour-infiltrating immune cells [IC] covering ≥5% of the tumour area), and who are not eligible for cisplatin-containing chemotherapy. Treatment with atezolizumab should be stopped at 2 years, or earlier if disease progresses.	No subsidy	1800	600
Atezolizumab	Atezolizumab concentrate for solution for infusion (840 mg/14 mL, 1200 mg/20 mL)	Tecentriq	Treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status. Treatment with atezolizumab should be stopped at 2 years, or earlier if disease progresses.	No subsidy	1800	600
Atezolizumab	Atezolizumab concentrate for solution for infusion (840 mg/14 mL, 1200 mg/20 mL)	Tecentriq	Treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) after receiving platinum-containing chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for UC. Treatment with atezolizumab should be stopped at 2 years, or earlier if disease progresses.	No subsidy	1800	600
Atezolizumab	Atezolizumab concentrate for solution for infusion (840 mg/14 mL, 1200 mg/20 mL)	Tecentriq	Atezolizumab in combination with bevacizumab for treating advanced unresectable hepatocellular carcinoma in patients who have not received prior systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system.	No subsidy	1800	600
Avelumab	Avelumab concentrate for solution for infusion (200 mg/10 mL)	Bavencio	Treatment of metastatic merkel cell carcinoma.	No subsidy	1800	600
Avelumab	Avelumab concentrate for solution for infusion (200 mg/10 mL)	Bavencio	Avelumab in combination with axitinib for untreated advanced renal cell carcinoma. Treatment with PD-1/PD-L1 inhibitor should be stopped at 2 years, or earlier if disease progresses.	No subsidy	1800	600
Avelumab	Avelumab concentrate for solution for infusion (200 mg/10 mL)	Bavencio	Maintenance treatment of locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-based chemotherapy.	No subsidy	1800	600
Axitinib	Axitinib tablet (1 mg, 5 mg)	Inlyta	For previously treated advanced renal cell carcinoma.	No subsidy	1600	600
Azacitidine	Azacitidine injection (100 mg)	-	For cancer treatment.	SDL	400	600
Bacillus Calmette-Guerin (BCG)	Bacillus Calmette-Guerin (BCG) solution for intravesical use (12.5 mg, 40 mg, 80 mg)	-	For cancer treatment.	SDL	400	600
Bendamustine	Bendamustine concentrate for infusion (25 mg and 100 mg)	-	For cancer treatment.	SDL	800	600
Bevacizumab	Bevacizumab concentrate for solution for infusion (100 mg/4 mL, 400 mg/16 mL)	(Undergoing Evaluation)	(Undergoing Evaluation)	(Undergoing Evaluation)	(Undergoing Evaluation)	(Undergoing Evaluation)
Bicalutamide	Bicalutamide tablet (50 mg)	-	For cancer treatment.	SDL	200	600
Bleomycin	Bleomycin injection (15 USP unit)	-	For cancer treatment.	SDL	400	600
Blinatumomab	Blinatumomab powder for infusion (35 mcg vial)	Blincyto	Treatment of B-cell precursor acute lymphoblastic leukaemia in first or subsequent complete remission with minimal residual disease (MRD) greater than or equal to 0.1% for: - up to a maximum of one cycle for induction in a lifetime; - and up to three additional cycles for consolidation in a lifetime in patients who are MRD negative. Complete remission is defined as a patient who: a) has 5% or less bone marrow blasts; and b) has no evidence of disease; and c) has a full recovery of peripheral blood counts with platelet count of more than 100,000 per microlitre; and d) absolute neutrophil count of more than 1,000 per microlitre	MAF	9600	1200
Blinatumomab	Blinatumomab powder for infusion (35 mcg vial)	Blincyto	Treatment of relapsed or refractory B-precursor acute lymphoblastic leukaemia (r/r B-ALL) for: - up to a maximum of two cycles for induction in a lifetime; and - up to three additional cycles for consolidation in a lifetime in patients who achieve a complete response after induction. Patients with Philadelphia chromosome positive disease must have previously received a tyrosine kinase inhibitor before receiving blinatumomab. Patients must not have received blinatumomab previously for the treatment of minimal residual disease (MRD)-positive B-ALL OR patients must have had a relapse-free period of at least six months following completion of treatment with blinatumomab for MRD. Complete response is defined as a patient who: - has 5% or less bone marrow blasts; and - has no evidence of disease; and - has platelet count of more than 50,000 per microlitre; and - has absolute neutrophil count of more than 500 per microlitre.	MAF	9600	1200
Bortezomib	Bortezomib injection (3.5mg)	(Undergoing Evaluation)	(Undergoing Evaluation)	(Undergoing Evaluation)	(Undergoing Evaluation)	(Undergoing Evaluation)
Brentuximab vedotin	Brentuximab vedotin powder for infusion (50 mg)	Adcetris	Brentuximab in combination with cyclophosphamide, doxorubicin and prednisone (CHP), for previously untreated CD30+ peripheral T-cell lymphoma.	MAF	1800	600
Brentuximab vedotin	Brentuximab vedotin powder for infusion (50 mg)	Adcetris	Treatment of relapsed or refractory systemic anaplastic large cell lymphoma. Treatment should be stopped at 16 cycles, or earlier if disease progresses.	MAF	1800	600
Brentuximab vedotin	Brentuximab vedotin powder for infusion (50 mg)	Adcetris	Treatment of patients with CD30+ cutaneous T-cell lymphoma who have received at least 1 prior systemic therapy. Treatment should be stopped at 16 cycles, or earlier if disease progresses.	MAF	1800	600
Brentuximab vedotin	Brentuximab vedotin powder for infusion (50 mg)	Adcetris	Treatment of adults with previously untreated CD30+ advanced classic Hodgkin lymphoma (cHL) in combination with doxorubicin, vinblastine and dacarbazine (AVD).	No subsidy	1800	600
Brentuximab vedotin	Brentuximab vedotin powder for infusion (50 mg)	Adcetris	Treatment of adults with CD30+ Hodgkin lymphoma (HL) who are at increased risk of relapse or progression following an autologous stem cell transplant (ASCT). Treatment should be stopped at 16 cycles, or earlier if disease progresses.	No subsidy	1800	600
Brentuximab vedotin	Brentuximab vedotin powder for infusion (50 mg)	Adcetris	Treatment of adults with relapsed or refractory CD30+ Hodgkin lymphoma (HL): 1. following autologous stem cell transplant (ASCT) or 2. following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option. Treatment should be stopped at 16 cycles, or earlier if disease progresses.	MAF	1800	600
Brigatinib	Brigatinib tablet (30 mg, 90 mg, 180 mg)	Alunbrig	Treatment of locally advanced or metastatic ALK- positive non-small cell lung cancer.	MAF	2000	600
Busulfan	Busulfan tablet (2 mg)	-	For cancer treatment.	SDL	200	600
Cabazitaxel	Cabazitaxel injection (60 mg/1.5 mL)	Jevtana	Cabazitaxel in combination with prednisolone: for the treatment of adult patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with a docetaxel-containing regimen.	No subsidy	1400	600
Cabozantinib	Cabozantinib tablet (20 mg, 40 mg, 60 mg)	Cabometyx	For previously treated advanced renal cell carcinoma.	No subsidy	1800	600
Cabozantinib	Cabozantinib tablet (20 mg, 40 mg, 60 mg)	Cabometyx	Treatment of advanced unresectable hepatocellular carcinoma in patients with disease progression after 1 or more prior lines of systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system.	No subsidy	1800	600
Cabozantinib	Cabozantinib tablet (20 mg, 40 mg, 60 mg)	Cabometyx	For untreated intermediate- or poor-risk advanced renal cell carcinoma.	No subsidy	1800	600
Capecitabine	Capecitabine tablet (150 mg, 500 mg)	-	For cancer treatment.	SDL	200	600
Carboplatin	Carboplatin vial (150 mg/15 mL, 450 mg/45 mL)	-	For cancer treatment.	SDL	200	600
Carfilzomib	Carfilzomib powder for solution for infusion (30 mg)	Kyprolis	Carfilzomib in combination with lenalidomide or thalidomide or cyclophosphamide, plus dexamethasone, for patients with multiple myeloma who have received at least one prior therapy. Treatment with carfilzomib should be stopped after 18 cycles, or earlier if disease progresses.	MAF	2000	600
Carfilzomib	Carfilzomib powder for solution for infusion (30 mg)	Kyprolis	Carfilzomib in combination with dexamethasone for patients with multiple myeloma who have received at least one prior therapy.	MAF	2000	600
Carmustine	Carmustine injection (100 mg)	BiCNU	For cancer treatment.	SDL	2000	600
Ceritinib	Ceritinib capsule (150 mg)	Zykadia	For cancer treatment.	SDL	1000	600
Cetuximab	Cetuximab solution for infusion (100 mg/20 mL)	Erbitux	Cetuximab in combination with platinum-based chemotherapy for patients with unresectable, recurrent or metastatic squamous cell cancer of the head and neck (RMSCCHN).	MAF	1000	600
Cetuximab	Cetuximab solution for infusion (100 mg/20 mL)	Erbitux	Cetuximab in combination with radiation therapy for patients with locally advanced squamous cell cancer of the head and neck (LASCCHN) who have contraindications or intolerance to platinum-based chemoradiation therapy.	MAF	1000	600
Cetuximab	Cetuximab solution for infusion (100 mg/20 mL)	Erbitux	Cetuximab as monotherapy or in combination with chemotherapy, for treating RAS wild-type metastatic colorectal cancer.	No subsidy	1000	600
Chlorambucil	Chlorambucil tablet (2 mg)	Leukeran	For cancer treatment.	SDL	400	600
Cisplatin	Cisplatin injection (50 mg/50 mL, 100 mg/100 mL injection)	-	For cancer treatment.	SDL	200	600
Crizotinib	Crizotinib capsule (200 mg, 250 mg)	Xalkori	Treatment of patients with locally advanced or metastatic ROS1-positive NSCLC. Patients must not have received prior treatment with other ROS1 inhibitors.	No subsidy	3000	600
Cyclophosphamide	Cyclophosphamide vial (1 g) and tablet (50 mg)	Endoxan	For cancer treatment.	SDL	200	600
Cyproterone	Cyproterone tablet (50 mg)	-	For cancer treatment.	SDL	200	600
Cytarabine	Cytarabine vial (1 g/10 mL)	-	For cancer treatment.	SDL	400	600
Dabrafenib plus trametinib	Dabrafenib capsule (50 mg, 75 mg) Trametinib tablet (0.5 mg, 2 mg)	Tafinlar Mekinist	Dabrafenib in combination with trametinib for treating locally advanced or metastatic anaplastic thyroid cancer in patients with a BRAF V600 mutation and with no satisfactory locoregional treatment options.	MAF	3800	600
Dabrafenib plus trametinib	Dabrafenib capsule (50 mg, 75 mg) Trametinib tablet (0.5 mg, 2 mg)	Tafinlar Mekinist	Dabrafenib in combination with trametinib for the adjuvant treatment of completely resected malignant melanoma in patients with BRAF V600 mutation-positive disease and lymph node involvement. Maximum duration of treatment: 12 months.	No subsidy	3800	600
Dabrafenib plus trametinib	Dabrafenib capsule (50 mg, 75 mg) Trametinib tablet (0.5 mg, 2 mg)	Tafinlar Mekinist	Dabrafenib in combination with trametinib for the treatment of advanced unresectable or metastatic malignant melanoma in patients with a BRAF V600 mutation. Patients must not have received prior treatment with a BRAF/MEK inhibitor for unresectable or metastatic melanoma.	MAF	3800	600
Dabrafenib plus trametinib	Dabrafenib capsule (50 mg, 75 mg) Trametinib tablet (0.5 mg, 2 mg)	Tafinlar Mekinist	Dabrafenib in combination with trametinib for the treatment of advanced non-small cell lung cancer (NSCLC) in patients with a BRAF V600 mutation.	MAF	3800	600
Dacarbazine	Dacarbazine vial (200 mg)	-	For cancer treatment.	SDL	600	600
Dacomitinib	Dacomitinib tablet (15 mg, 30 mg, 45 mg)	Vizimpro	For cancer treatment.	SDL	600	600
Dactinomycin	Dactinomycin vial (500 mcg)	-	For cancer treatment.	SDL	1400	600
Daratumumab	Daratumumab concentrate for solution for infusion (100 mg/5 mL, 400 mg/20 mL) and SC solution for injection (1800 mg/15 mL)	Darzalex	Daratumumab in combination with bortezomib, thalidomide and dexamethasone for patients with newly diagnosed multiple myeloma who are eligible for an autologous stem cell transplant.	No subsidy	2000	600
Daratumumab	Daratumumab concentrate for solution for infusion (100 mg/5 mL, 400 mg/20 mL) and SC solution for injection (1800 mg/15 mL)	Darzalex	Daratumumab in combination with lenalidomide and dexamethasone for patients with multiple myeloma who have received at least one prior therapy.	No subsidy	2000	600
Daratumumab	Daratumumab concentrate for solution for infusion (100 mg/5 mL, 400 mg/20 mL) and SC solution for injection (1800 mg/15 mL)	Darzalex	Daratumumab in combination with bortezomib and dexamethasone for patients with multiple myeloma who have received at least one prior therapy.	No subsidy	2000	600
Daratumumab	Daratumumab concentrate for solution for infusion (100 mg/5 mL, 400 mg/20 mL) and SC solution for injection (1800 mg/15 mL)	Darzalex	Daratumumab in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma who are ineligible for an autologous stem cell transplant.	No subsidy	2000	600
Darolutamide	Darolutamide tablet (300 mg)	Nubeqa	Treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC).	No subsidy	400	600
Dasatinib	Dasatinib tablet (20 mg, 50 mg, 70 mg)	Sprycel	Treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase.	MAF	1200	600
Dasatinib	Dasatinib tablet (20 mg, 50 mg, 70 mg)	Sprycel	Treatment of adults with treatment-resistant or treatment-intolerant chronic myeloid leukemia (CML) in chronic phase, accelerated phase, or myeloid or lymphoid blast phase or children with treatment-resistant or treatment-intolerant CML in chronic phase.	MAF	1200	600
Dasatinib	Dasatinib tablet (20 mg, 50 mg, 70 mg)	Sprycel	Treatment of newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia in combination with chemotherapy.	MAF	1200	600
Dasatinib	Dasatinib tablet (20 mg, 50 mg, 70 mg)	Sprycel	Treatment of adults with Philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior treatment with imatinib.	MAF	1200	600
Daunorubicin	Daunorubicin vial (20 mg )	-	For cancer treatment.	SDL	400	600
Degarelix	Degarelix injection (80 mg, 120 mg)	Firmagon	Treatment of adults with advanced hormone-dependent prostate cancer.	MAF	200	600
Dexamethasone	Dexamethasone injection (4 mg) and tablet (4 mg)	-	For cancer treatment.	SDL	200	600
Docetaxel	Docetaxel vial (20 mg , 80 mg, 160 mg)	-	For cancer treatment.	SDL	200	600
Doxorubicin	Doxorubicin vial (50 mg)	-	For cancer treatment.	SDL	200	600
Durvalumab	Durvalumab concentrate for solution for infusion (120 mg/2.4 mL, 500 mg/10 mL)	Imfinzi	Consolidation treatment of patients with locally advanced, unresectable NSCLC whose disease has not progressed following platinum-based chemo-radiation therapy. Treatment should be continued until disease progression or unacceptable toxicity or a maximum of 12 months.	MAF	1800	600
Durvalumab	Durvalumab concentrate for solution for infusion (120 mg/2.4 mL, 500 mg/10 mL)	Imfinzi	Durvalumab in combination with a platinum agent and etoposide, for previously untreated extensive-stage small cell lung cancer.	MAF	1800	600
Entrectinib	Entrectinib capsule (100 mg, 200 mg)	Rozlytrek	Treatment of patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer. Patients must not have received prior treatment with other ROS1 inhibitors.	No subsidy	3000	600
Entrectinib	Entrectinib capsule (100 mg, 200 mg)	Rozlytrek	Treatment of patients with solid tumours that: - have a NTRK gene fusion without a known acquired resistance mutation, - are metastatic or where surgical resection is likely to result in severe morbidity, and - have no satisfactory alternative treatments or that have progressed following treatment.	No subsidy	3000	600
Enzalutamide	Enzalutamide capsule (40 mg)	Xtandi	Treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC).	MAF	400	600
Enzalutamide	Enzalutamide capsule (40 mg)	Xtandi	Treatment of adult men with metastatic hormone sensitive prostate cancer (mHSPC).	MAF	400	600
Enzalutamide	Enzalutamide capsule (40 mg)	Xtandi	Treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC).	MAF	400	600
Epirubicin	Epirubicin injection (50 mg/25 mL)	-	For cancer treatment.	SDL	600	600
Erdafitinib	Erdafitinib tablet (3 mg, 4 mg, 5 mg)	Balversa	Treatment of patients with locally advanced or metastatic urothelial carcinoma, whose tumours have susceptible FGFR3 genetic alterations, and who have disease progression during or following at least one line of prior chemotherapy including within 12 months of neoadjuvant or adjuvant chemotherapy.	No subsidy	1800	600
Eribulin	Eribulin mesylate solution for injection (1 mg/2 mL)	Halaven	Treatment of locally advanced or metastatic breast cancer in patients whose disease has progressed after >= 2 chemotherapy regimens for advanced disease.	MAF	1200	600
Eribulin	Eribulin mesylate solution for injection (1 mg/2 mL)	Halaven	Treatment of adults with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease.	MAF	1200	600
Erlotinib	Erlotinib tablet (100 mg, 150 mg)	-	For cancer treatment.	SDL (Inerlotinib)	200	600
Etoposide	Etoposide capsule (50 mg)	-	For cancer treatment.	SDL	600	600
Etoposide	Etoposide vial (100 mg/5 mL)	-	For cancer treatment.	SDL	200	600
Everolimus	Everolimus tablet (2.5 mg, 5 mg, 10 mg)	Afinitor	Everolimus in combination with exemestine for HR positive, HER2/neu negative advanced breast cancer, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.	No subsidy	1200	600
Everolimus	Everolimus tablet (2.5 mg, 5 mg, 10 mg)	Afinitor	For previously treated advanced renal cell carcinoma.	No subsidy	1200	600
Everolimus	Everolimus tablet (2.5 mg, 5 mg, 10 mg)	Afinitor	Treatment of unresectable, locally advanced or metastatic neuroendocrine tumours of pancreatic origin and with progressive disease.	MAF	1200	600
Everolimus	Everolimus tablet (2.5 mg, 5 mg, 10 mg)	Afinitor	Treatment of unresectable or metastatic, well-differentiated, non-functional neuroendocrine tumours of gastrointestinal or lung origin and with progressive disease.	MAF	1200	600
Exemestane	Exemestane tablet (25 mg)	-	For cancer treatment.	SDL	200	600
Fludarabine	Fludarabine injection (50 mg)	-	For cancer treatment.	SDL	600	600
Fluorouracil	Fluorouracil vial (500 mg/10 mL, 1g/20 mL, 5g/100 mL)	-	For cancer treatment.	SDL	200	600
Fluorouracil (5-fluorouracil) cream	5-fluorouracil cream (5%)	-	Treatment of actinic keratosis, Bowen’s disease, or superficial basal cell carcinoma.	No subsidy	200	600
Folinic acid	Folinic acid vial (50 mg/5 mL, 300 mg/30 mL)	-	For cancer treatment.	SDL	200	600
Fulvestrant	Fulvestrant solution for injection in pre-filled syringe (250 mg/5 mL)	(Undergoing Evaluation)	(Undergoing Evaluation)	(Undergoing Evaluation)	(Undergoing Evaluation)	(Undergoing Evaluation)
Gefitinib	Gefitinib tablet (250 mg)	-	For cancer treatment.	SDL (Ingefitinib)	200	600
Gemcitabine	Gemcitabine vial (200 mg, 1 g, 2 g)	-	For cancer treatment.	SDL	200	600
Gilteritinib	Gilteritinib tablet (40 mg)	Xospata	Treatment of FLT-3 mutation positive relapsed / refractory acute myeloid leukaemia (AML). Gilteritinib is not recommended as maintenance therapy for patients after HSCT.	(Undergoing Evaluation)	(Undergoing Evaluation)	(Undergoing Evaluation)
Goserelin	Goserelin depot injection (3.6 mg, 10.8 mg)	Zoladex	Treatment of breast cancer in pre- and perimenopausal women in whom hormone therapy is specified.	MAF	200	600
Goserelin	Goserelin depot injection (3.6 mg, 10.8 mg)	Zoladex	1) As primary therapy for men with locally advanced or metastatic prostate cancer 2) As neoadjuvant therapy, for 3 months to 2 years, in men receiving radical radiotherapy 3) For men with prostate cancer who have a biochemical relapse. LHRH agonist is not recommended as monotherapy in patients with low risk prostate cancer	MAF	200	600
Hydroxyurea	Hydroxyurea capsule (500 mg)	-	For cancer treatment.	SDL	200	600
Ibrutinib	Ibrutinib capsule (140 mg) and tablet (140 mg, 280 mg, 420 mg)	Imbruvica	Monotherapy for patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are unsuitable for fludarabine-based therapy.	No subsidy	2000	600
Ibrutinib	Ibrutinib capsule (140 mg) and tablet (140 mg, 280 mg, 420 mg)	Imbruvica	Ibrutinib in combination with rituximab biosimilar or obinutuzumab for previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).	No subsidy	2000	600
Ibrutinib	Ibrutinib capsule (140 mg) and tablet (140 mg, 280 mg, 420 mg)	Imbruvica	Monotherapy for patients with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least one prior therapy.	No subsidy	2000	600
Ibrutinib	Ibrutinib capsule (140 mg) and tablet (140 mg, 280 mg, 560 mg)	Imbruvica	Treatment of adults with mantle cell lymphoma (MCL) who have received at least one prior therapy.	No subsidy	2000	600
Ibrutinib	Ibrutinib capsule (140 mg) and tablet (140 mg, 280 mg, 420 mg)	Imbruvica	Ibrutinib as a single agent, or in combination with rituximab biosimilar, for the treatment of Waldenstrom’s Macroglobulinaemia.	No subsidy	2000	600
Idarubicin	Idarubicin solution for injection (5 mg/5 mL and 10 mg/10 mL)	Zavedos CS	Treatment of acute myeloid leukaemia (AML) in adults for remission induction.	No subsidy	400	600
Ifosfamide	Ifosfamide infusion (1 g)	Holoxan	For cancer treatment.	SDL	2400	600
Imatinib	Imatinib tablet (100 mg, 400 mg)	-	For cancer treatment.	SDL (Veenat)	200	600
Imiquimod cream	Imiquimod cream (5%)	Aldara	Treatment of actinic keratosis or superficial basal cell carcinoma.	No subsidy	200	600
Inotuzumab ozogamicin	Inotuzumab ozogamicin powder for concentrate for solution for infusion (1 mg per vial)	Besponsa	Treatment of adults with relapsed or refractory CD22 positive B-cell precursor acute lymphoblastic leukemia (ALL) for: - up to a maximum of three cycles for induction in a lifetime, and - up to three additional cycles for consolidation in a lifetime in patients who achieve a complete response after induction Patients with Philadelphia chromosome positive disease must have previously received a tyrosine kinase inhibitor before receiving inotuzumab. Complete response is defined as a patient who: a) has 5% or less bone marrow blasts; and b) has no evidence of disease; and c) has platelet count of more than 50,000 per microlitre; and d) has absolute neutrophil count of more than 500 per microlitre.	MAF	9600	1200
Interferon alfa 2a	Interferon alfa 2a injection (3 million iu/ 0.5 mL)	-	For cancer treatment.	SDL	400	600
Ipilimumab plus nivolumab	Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL) Ipilimumab injection concentrate (50 mg/10 mL)	Opdivo Yervoy	For untreated intermediate- or poor-risk advanced renal cell carcinoma. The doses of nivolumab and ipilimumab should not exceed: 3mg/kg nivolumab and 1mg/kg ipilimumab every 3 weeks for 4 doses. Re-induction with ipilimumab is not allowed.	MAF	5200	600
Irinotecan hydrochloride trihydrate	Irinotecan hydrochloride trihydrate vial (100 mg/5 mL)	-	For cancer treatment.	SDL	200	600
Ixazomib	Ixazomib capsule (3 mg, 4 mg)	Ninlaro	Ixazomib in combination with lenalidomide and dexamethasone for patients with multiple myeloma who have received at least one prior therapy.	MAF	2000	600
Lanreotide	Lanreotide prolonged release (PR) injection (60 mg, 90 mg, 120 mg)	Somatuline Autogel	Treatment of neuroendocrine tumours of gastrointestinal or pancreatic origin.	No subsidy	600	600
Lanreotide	Lanreotide prolonged release (PR) injection (60 mg, 90 mg, 120 mg)	Somatuline Autogel	For the reduction of symptoms associated with carcinoid syndrome.	No subsidy	600	600
Lapatinib	Lapatinib tablet (250 mg)	Tykerb	Lapatinib in combination with an aromatase inhibitor for postmenopausal women with HR positive, HER2 positive metastatic breast cancer.	MAF	600	600
Lapatinib	Lapatinib tablet (250 mg)	Tykerb	Lapatinib in combination with capecitabine for HER2 positive, advanced or metastatic breast cancer in patients whose disease has progressed after treatment with an anthracycline and, a taxane, and on prior trastuzumab therapy in the metastatic setting.	MAF	600	600
Larotrectinib	Larotrectinib capsule (25 mg, 100 mg) and oral solution (2 g/100 mL)	Vitrakvi	Treatment of patients with solid tumours that: - have a NTRK gene fusion without a known acquired resistance mutation, - are metastatic or where surgical resection is likely to result in severe morbidity, and - have no satisfactory alternative treatments or that have progressed following treatment.	No subsidy	3000	600
L-asparaginase	L-asparaginase injection (10,000 IU)	Leunase	For cancer treatment.	SDL	1000	600
Lenalidomide	Lenalidomide capsule (5 mg, 10 mg, 15 mg, 25 mg)	-	For cancer treatment.	SDL (Lenli)	1200	600
Lenvatinib	Lenvatinib capsule (4 mg, 10 mg)	Lenvima	Treatment of advanced unresectable hepatocellular carcinoma in patients with adequate liver function as assessed by the Child-Pugh scoring system, when used according to HSA-recommended dosing regimens.	MAF	1200	600
Lenvatinib	Lenvatinib capsule (4 mg, 10 mg)	Lenvima	Treatment of locally advanced or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.	MAF	1200	600
Lenvatinib	Lenvatinib capsule (4 mg, 10 mg)	Lenvima	Lenvatinib in combination with everolimus for previously treated advanced renal cell carcinoma.	No subsidy	1200	600
Letrozole	Letrozole tablet (2.5 mg)	-	For cancer treatment.	SDL	200	600
Leuprorelin	Leuprorelin acetate injection (3.75 mg)	Lucrin	Treatment of breast cancer in pre- and perimenopausal women in whom hormone therapy is specified.	MAF	200	600
Leuprorelin	Leuprorelin acetate injection (3.75 mg, 5 mg/ml, 7.5 mg, 11.25 mg, 22.5 mg, 30 mg, 45 mg)	Lucrin Eligard	1) As primary therapy for men with locally advanced or metastatic prostate cancer 2) As neoadjuvant therapy, for 3 months to 2 years, in men receiving radical radiotherapy 3) For men with prostate cancer who have a biochemical relapse. LHRH agonist is not recommended as monotherapy in patients with low risk prostate cancer	MAF	200	600
Liposomal doxorubicin	Doxorubicin hydrochloride (pegylated liposome) concentrate for infusion (20 mg/10 mL)	-	For cancer treatment.	SDL (Chemodox)	1400	600
Liposomal irinotecan	Pegylated liposomal irinotecan concentrate for dispersion for infusion (43 mg/10 mL)	Onivyde	Liposomal irinotecan in combination with fluorouracil and leucovorin, for patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.	No subsidy	200	600
Lomustine	Lomustine capsule (40 mg)	-	For cancer treatment.	SDL	200	600
Lorlatinib	Lorlatinib tablet (25 mg, 100 mg)	Lorviqua	Treatment of patients with locally advanced or metastatic ALK-positive non-small cell lung cancer whose disease has progressed after an ALK inhibitor other than crizotinib.	No subsidy	2000	600
Lutetium oxodotreotide	Lutetium-177 (177-Lu) peptide	-	Treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor-positive gastro-entero-pancreatic neuroendocrine tumours (NETs), including foregut, midgut, and hindgut NETs in adults.	No subsidy	1200	600
Lutetium PSMA	Lutetium PSMA	-	Treatment of adults with metastatic castration resistant prostate cancer (mCRPC) previously treated with a docetaxel-containing regimen.	No subsidy	1400	600
Megestrol	Megestrol tablet (40 mg, 160 mg)	-	For cancer treatment.	SDL	200	600
Melphalan	Melphalan injection (50 mg)	Alkeran	For cancer treatment.	SDL	400	600
Melphalan	Melphalan tablet (2 mg)	Alkeran	For cancer treatment.	SDL	200	600
Mercaptopurine	Mercaptopurine tablet (50 mg)	-	For cancer treatment.	SDL	200	600
Meta-iodobenzylguanidine [I-131]	Meta-iodobenzylguanidine [I-131] injection for therapeutic use (185 to 740 MBq/mL)	-	Radiation therapy of tumours arising from cells originating embryologically from the neural crest, pheochromocytomas, neuroblastomas, carcinoids and medullary carcinomas of the thyroid gland.	No subsidy	3000	600
Methotrexate	Methotrexate vial (50 mg/2 mL, 1g/10 mL)	-	For cancer treatment.	SDL	400	600
Methotrexate	Methotrexate tablet (2.5 mg)	-	For cancer treatment.	SDL	200	600
Methylprednisolone	Methylprednisolone vial (62.5mg/mL)	-	For cancer treatment.	SDL	200	600
Midostaurin	Midostaurin tablet (25 mg)	Rydapt	Treatment of FLT-3-mutation positive acute myeloid leukaemia (AML) in combination with standard intensive induction and consolidation chemotherapy. Standard induction chemotherapy must include cytarabine and an anthracycline. Midostaurin is not recommended for maintenance therapy.	MAF	2400	600
Mitomycin	Mitomycin injection (2 mg, 10 mg)	-	For cancer treatment.	SDL	200	600
Mitoxantrone	Mitoxantrone vial (20 mg/10 mL)	-	For cancer treatment.	SDL	1000	600
Nab-paclitaxel	Paclitaxel - albumin bound nanoparticles injectable suspension (100 mg)	Abraxane	Monotherapy for breast cancer in adults who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated.	MAF	1000	600
Nab-paclitaxel	Paclitaxel - albumin bound nanoparticles injectable suspension (100 mg)	Abraxane	Nab-paclitaxel in combination with gemcitabine, for previously untreated metastatic adenocarcinoma of the pancreas.	MAF	1000	600
Nab-paclitaxel	Paclitaxel - albumin bound nanoparticles injectable suspension (100 mg)	Abraxane	Nab-paclitaxel in combination with carboplatin, for previously untreated locally advanced or metastatic non-small cell lung cancer in patients who are not candidates for curative surgery or radiation therapy.	MAF	1000	600
Nilotinib	Nilotinib capsule (50 mg, 150 mg, 200 mg)	Tasigna	Treatment of newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase.	MAF	1200	600
Nilotinib	Nilotinib capsule (50 mg, 150 mg, 200 mg)	Tasigna	Treatment of adults with treatment-resistant or treatment-intolerant chronic myeloid leukaemia (CML) in chronic phase or accelerated phase; or children with treatment-resistant or treatment-intolerant CML in chronic phase.	MAF	1200	600
Nivolumab	Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL)	Opdivo	Treatment of patients with unresectable locally advanced or recurrent gastric or gastroesophageal junction (GEJ) adenocarcinoma after 2 or more prior systemic therapies. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for gastric or GEJ cancer. The dose of nivolumab should not exceed 3mg/kg every 2 weeks. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses.	MAF	1800	600
Nivolumab	Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL)	Opdivo	Treatment of unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for MSI-H or dMMR CRC. The dose of nivolumab should not exceed 240mg every 2 weeks or 480mg every 4 weeks. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses.	No subsidy	1800	600
Nivolumab	Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL)	Opdivo	Nivolumab in combination with ipilimumab for treatment of unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for MSI-H or dMMR CRC. The doses of nivolumab and ipilimumab should not exceed: 3mg/kg nivolumab and 1mg/kg ipilimumab every 3 weeks for 4 doses, followed by nivolumab 240mg every 2 weeks or 480mg every 4 weeks as a single agent. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses. Re-induction with ipilimumab is not allowed.	No subsidy	1800	600
Nivolumab	Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL)	Opdivo	Treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for metastatic NSCLC. The dose of nivolumab should not exceed 3mg/kg every 2 weeks. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses.	MAF	1800	600
Nivolumab	Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL)	Opdivo	Treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) after receiving platinum-containing chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for UC. The dose of nivolumab should not exceed 3mg/kg every 2 weeks. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses.	No subsidy	1800	600
Nivolumab	Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL)	Opdivo	Treatment of advanced unresectable hepatocellular carcinoma (HCC) in patients with disease progression after 1 or more prior lines of systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for HCC. The dose of nivolumab should not exceed 3mg/kg every 2 weeks. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses.	No subsidy	1800	600
Nivolumab	Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL)	Opdivo	Nivolumab in combination with ipilimumab for treatment of advanced unresectable hepatocellular carcinoma (HCC) in patients with disease progression after 1 or more prior lines of systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for HCC. The doses of nivolumab and ipilimumab should not exceed: 1mg/kg nivolumab and 3mg/kg ipilimumab every 3 weeks for 4 doses, followed by nivolumab 240mg every 2 weeks or 480mg every 4 weeks as a single agent. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses. Re-induction with ipilimumab is not allowed.	No subsidy	1800	600
Nivolumab	Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL)	Opdivo	Nivolumab in combination with ipilimumab and 2 cycles of platinum-based chemotherapy, for previously untreated metastatic or recurrent non-small cell lung cancer (NSCLC) in patients with no EGFR or ALK genomic tumour mutations. The doses of nivolumab and ipilimumab should not exceed: 360mg nivolumab every 3 weeks and 1mg/kg ipilimumab every 6 weeks. Treatment with nivolumab and ipilimumab should be stopped at 2 years, or earlier if disease progresses.	No subsidy	1800	600
Nivolumab	Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL)	Opdivo	For previously treated advanced renal cell carcinoma (RCC). Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for RCC. The dose of nivolumab should not exceed 3mg/kg every 2 weeks. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses.	MAF	1800	600
Nivolumab	Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL)	Opdivo	Adjuvant treatment of completely resected malignant melanoma in patients with lymph node involvement. The dose of nivolumab should not exceed 3mg/kg every 2 weeks. Maximum duration of treatment: 12 months.	MAF	1800	600
Nivolumab	Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL)	Opdivo	Monotherapy for advanced unresectable or metastatic malignant melanoma. Patients must not have received prior treatment with a PD-1 inhibitor or ipilimumab for unresectable or metastatic melanoma. The dose of nivolumab should not exceed 3mg/kg every 2 weeks. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses.	MAF	1800	600
Nivolumab	Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL)	Opdivo	For untreated intermediate- or poor-risk advanced renal cell carcinoma, following induction treatment with nivolumab in combination with ipilimumab. The dose of nivolumab should not exceed 3mg/kg every 2 weeks. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses.	MAF	1800	600
Nivolumab	Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL)	Opdivo	Nivolumab in combination with ipilimumab for the treatment of advanced unresectable or metastatic malignant melanoma. Patients must not have received prior treatment with a PD-1 inhibitor or ipilimumab for unresectable or metastatic melanoma. The doses of nivolumab and ipilimumab should not exceed: 1mg/kg nivolumab and 3mg/kg ipilimumab every 3 weeks for 4 doses, followed by 3 mg/kg nivolumab every 2 weeks as a single agent. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses. Re-induction with ipilimumab is not allowed.	No subsidy	1800	600
Nivolumab	Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL)	Opdivo	For patients with unresectable, recurrent or metastatic squamous cell cancer of the head and neck (RMSCCHN) whose disease progressed within six months of starting platinum-based chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for RMSCCHN. The dose of nivolumab should not exceed 3mg/kg every 2 weeks. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses.	MAF	1800	600
Nivolumab	Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL)	Opdivo	Treatment of adults with relapsed or refractory classical Hodgkin lymphoma (cHL) after an autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for relapsed or refractory cHL. The dose of nivolumab should not exceed 3mg/kg every 2 weeks. Treatment with nivolumab should be stopped at 2 years, or earlier if the person has an allogeneic stem cell transplant or the disease progresses.	MAF	1800	600
Obinutuzumab	Obinutuzumab concentrate for solution for infusion (1000 mg/40 mL)	Gazyva	Obinutuzumab in combination with chemotherapy, for previously untreated stage II bulky, III or IV follicular lymphoma. Patients achieving at least a partial remission may continue to receive maintenance treatment with obinutuzumab monotherapy. Maintenance treatment with obinutuzumab should be stopped after 2 years, or earlier if disease progresses.	No subsidy	1800	600
Obinutuzumab	Obinutuzumab concentrate for solution for infusion (1000 mg/40 mL)	Gazyva	Obinutuzumab in combination with bendamustine, for the treatment of follicular lymphoma that has not responded to or progressed within 6 months after treatment with rituximab or a rituximab-containing regimen. Patients must not have received obinutuzumab for follicular lymphoma. Maintenance treatment with obinutuzumab should be stopped at 2 years, or earlier if disease progresses.	MAF	1800	600
Octreotide	Octreotide long-acting depot injection (20 mg, 30 mg)	Sandostatin LAR	For cancer treatment.	SDL	600	600
Olaparib	Olaparib tablet (100 mg, 150 mg)	Lynparza	Maintenance treatment of patients with deleterious or suspected deleterious germline BRCA mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen.	MAF	1600	600
Olaparib	Olaparib tablet (100 mg, 150 mg)	Lynparza	Treatment of germline BRCA-mutated, HER2 negative, locally advanced or metastatic breast cancer in patients previously treated with chemotherapy.	MAF	1600	600
Olaparib	Olaparib tablet (100 mg, 150 mg)	Lynparza	Treatment of adults with metastatic castration-resistant prostate cancer and homologous recombination repair gene BRCA1/2 and/or ATM-mutations (germline and/or somatic) who have progressed following a prior treatment with abiraterone or second generation anti-androgen.	MAF	1600	600
Olaparib	Olaparib tablet (100 mg, 150 mg)	Lynparza	Maintenance monotherapy for adults with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Treatment should be continued until disease progression or unacceptable toxicity or a maximum of 24 months.	MAF	1600	600
Olaparib	Olaparib tablet (100 mg, 150 mg)	Lynparza	Olaparib in combination with bevacizumab as maintenance treatment of adults with advanced homologous recombination deficiency (HRD) positive high grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy in combination with bevacizumab. Treatment with olaparib should be continued until disease progression or unacceptable toxicity or a maximum of 24 months.	MAF	1600	600
Olaparib	Olaparib tablet (100 mg, 150 mg)	Lynparza	Maintenance monotherapy for adults with platinum-sensitive relapsed BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Patients must not have received prior treatment with a PARP inhibitor for ovarian cancer. Treatment should be continued until disease progression or unacceptable toxicity.	MAF	1600	600
Osimertinib	Osimertinib tablet (40 mg, 80 mg)	Tagrisso	For previously untreated locally advanced or metastatic EGFR mutation positive non-small cell lung cancer.	No subsidy	600	600
Osimertinib	Osimertinib tablet (40 mg, 80 mg)	Tagrisso	Treatment of patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC whose disease has progressed on or after EGFR TKI therapy.	MAF	600	600
Osimertinib	Osimertinib tablet (40 mg, 80 mg)	Tagrisso	Adjuvant treatment after tumour resection in patients with stage IB to IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. Treatment should be continued until disease recurrence or unacceptable toxicity or a maximum of 3 years.	No subsidy	600	600
Oxaliplatin	Oxaliplatin injection (50 mg/10 mL, 100 mg/50 mL, 200 mg/40 mL)	-	For cancer treatment.	SDL	200	600
Paclitaxel	Paclitaxel vial (150 mg/25 mL, 300 mg/50 mL)	-	For cancer treatment.	SDL	200	600
Palbociclib	Palbociclib capsule (75 mg, 100 mg, 125 mg)	Ibrance	Palbociclib in combination with an aromatase inhibitor as initial endocrine-based therapy for HR positive, HER2 negative, advanced or metastatic breast cancer.	MAF	800	600
Palbociclib	Palbociclib capsule (75 mg, 100 mg, 125 mg)	Ibrance	Palbociclib in combination with fulvestrant for treating HR positive, HER2 negative, advanced or metastatic breast cancer in patients who have received prior endocrine therapy.	MAF	800	600
Panitumumab	Panitumumab concentrate for solution for infusion (100 mg/5 mL)	Vectibix	For cancer treatment.	SDL	1000	600
Pazopanib	Pazopanib tablet (200 mg, 400 mg)	Votrient	For cancer treatment.	SDL	1600	600
Pembrolizumab	Pembrolizumab solution for infusion (100 mg/4 mL)	Keytruda	Adjuvant treatment of completely resected malignant melanoma in patients with lymph node involvement. Maximum duration of treatment: 12 months.	MAF	1800	600
Pembrolizumab	Pembrolizumab solution for infusion (100 mg/4 mL)	Keytruda	Treatment of advanced unresectable or metastatic malignant melanoma. Patients must not have received a PD-1 inhibitor or ipilimumab for unresectable or metastatic melanoma. Treatment with PD-1 inhibitor should be stopped at 2 years, or earlier if disease progresses.	MAF	1800	600
Pembrolizumab	Pembrolizumab solution for infusion (100 mg/4 mL)	Keytruda	Treatment of metastatic Merkel cell carcinoma.	MAF	1800	600
Pembrolizumab	Pembrolizumab solution for infusion (100 mg/4 mL)	Keytruda	Pembrolizumab in combination with axitinib for untreated advanced renal cell carcinoma. Treatment with PD-1/PD-L1 inhibitor should be stopped at 2 years, or earlier if disease progresses.	No subsidy	1800	600
Pembrolizumab	Pembrolizumab solution for infusion (100 mg/4 mL)	Keytruda	Monotherapy for previously untreated unresectable, recurrent or metastatic squamous cell cancer of the head and neck (RMSCCHN) with PD-L1 CPS≥1. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses.	MAF	1800	600
Pembrolizumab	Pembrolizumab solution for infusion (100 mg/4 mL)	Keytruda	Pembrolizumab in combination with platinum-based chemotherapy, for previously untreated unresectable, recurrent or metastatic squamous cell cancer of the head and neck (RMSCCHN) with PD-L1 CPS≥1. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses.	MAF	1800	600
Pembrolizumab	Pembrolizumab solution for infusion (100 mg/4 mL)	Keytruda	Pembrolizumab in combination with lenvatinib for treating advanced endometrial carcinoma that is not microsatellite instability-high (non-MSI-H) or mismatch repair deficient (non-dMMR), who have disease progression following prior chemotherapy in the metastatic setting and are not candidates for curative surgery or radiation.	No subsidy	1800	600
Pembrolizumab	Pembrolizumab solution for infusion (100 mg/4 mL)	Keytruda	For previously untreated metastatic non-small cell lung cancer (NSCLC) in patients whose tumours express PD-L1 with a tumour proportion score ≥50%, with no EGFR or ALK genomic tumour aberrations.Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses.	MAF	1800	600
Pembrolizumab	Pembrolizumab solution for infusion (100 mg/4 mL)	Keytruda	Treatment of patients with metastatic non-small cell lung cancer (NSCLC), whose tumours express PD-L1 with a tumour proportion score ≥1% and had disease progression during or following platinum-containing chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for metastatic NSCLC. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses.	MAF	1800	600
Pembrolizumab	Pembrolizumab solution for infusion (100 mg/4 mL)	Keytruda	Pembrolizumab in combination with carboplatin and nab- paclitaxel for previously untreated metastatic squamous non-small cell lung cancer (NSCLC). Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses.	No subsidy	1800	600
Pembrolizumab	Pembrolizumab solution for infusion (100 mg/4 mL)	Keytruda	Pembrolizumab in combination with carboplatin and paclitaxel for previously untreated metastatic squamous non-small cell lung cancer (NSCLC). Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses.	MAF	1800	600
Pembrolizumab	Pembrolizumab solution for infusion (100 mg/4 mL)	Keytruda	Pembrolizumab in combination with pemetrexed and platinum chemotherapy, for previously untreated metastatic non-squamous non-small cell lung cancer (NSCLC) in patients with no EGFR or ALK genomic tumour aberrations. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses.	MAF	1800	600
Pembrolizumab	Pembrolizumab solution for infusion (100 mg/4 mL)	Keytruda	Treatment of advanced unresectable hepatocellular carcinoma (HCC) in patients with disease progression after 1 or more prior lines of systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for HCC. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses.	No subsidy	1800	600
Pembrolizumab	Pembrolizumab solution for infusion (100 mg/4 mL)	Keytruda	Treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumours that have progressed following prior treatment and who have no satisfactory alternative treatment options. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for a MSI-H or dMMR solid tumour. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses.	No subsidy	1800	600
Pembrolizumab	Pembrolizumab solution for infusion (100 mg/4 mL)	Keytruda	Treatment of patients with locally advanced or metastatic urothelial carcinoma whose tumours express PD-L1 with a combined positive score (CPS) ≥10, and who are not eligible for cisplatin-containing chemotherapy. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses.	No subsidy	1800	600
Pembrolizumab	Pembrolizumab solution for infusion (100 mg/4 mL)	Keytruda	Treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses.	No subsidy	1800	600
Pembrolizumab	Pembrolizumab solution for infusion (100 mg/4 mL)	Keytruda	Treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) after receiving platinum-containing chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for UC. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses.	MAF	1800	600
Pembrolizumab	Pembrolizumab solution for infusion (100 mg/4 mL)	Keytruda	Treatment of patients with refractory classical Hodgkin lymphoma (cHL), or who have relapsed after 3 or more prior lines of therapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for relapsed or refractory cHL. Treatment with pembrolizumab should be stopped at 2 years, or earlier if the person has a stem cell transplant or the disease progresses.	MAF	1800	600
Pemetrexed	Pemetrexed injection (100 mg, 500 mg)	-	For cancer treatment.	SDL	200	600
Pertuzumab	Pertuzumab concentrate for solution for infusion (420 mg/14 mL)	Perjeta	Pertuzumab in combination with trastuzumab and chemotherapy for neoadjuvant treatment of HER2 positive locally advanced, inflammatory or early stage (tumour >2 cm in diameter or node positive) breast cancer for 4 to 6 cycles. Following surgery, patients may continue with trastuzumab with or without pertuzumab for a total of 1 year of anti-HER2 treatment.	No subsidy	2400	600
Pertuzumab	Pertuzumab concentrate for solution for infusion (420 mg/14 mL)	Perjeta	Pertuzumab in combination with trastuzumab and chemotherapy for adjuvant treatment of high-risk (with positive nodes) HER2 positive early breast cancer for a maximum duration of 1 year.	No subsidy	2400	600
Pertuzumab	Pertuzumab concentrate for solution for infusion (420 mg/14 mL)	Perjeta	Pertuzumab in combination with trastuzumab and a taxane for HER2 positive metastatic or locally recurrent breast cancer, in patients without prior treatment for metastatic disease. Treatment with pertuzumab should be stopped if disease progresses.	No subsidy	2400	600
Pertuzumab + trastuzumab	Pertuzumab / trastuzumab solution for subcutaneous injection (1200 mg/600 mg, 600 mg/600 mg)	Phesgo	In combination with chemotherapy for neoadjuvant treatment of HER2-positive locally advanced, inflammatory or early stage (tumour >2 cm in diameter or node positive) breast cancer for 4 to 6 cycles. Following surgery, patients may continue with trastuzumab with or without pertuzumab for a total of 1 year of anti-HER2 treatment.	No subsidy	2400	600
Pertuzumab + trastuzumab	Pertuzumab / trastuzumab solution for subcutaneous injection (1200 mg/600 mg, 600 mg/600 mg)	Phesgo	In combination with chemotherapy for adjuvant treatment of high-risk (with positive nodes) HER2-positive early breast cancer for a maximum duration of 1 year.	No subsidy	2400	600
Pertuzumab + trastuzumab	Pertuzumab / trastuzumab solution for subcutaneous injection (1200 mg/600 mg, 600 mg/600 mg)	Phesgo	In combination with a taxane for treating HER2-positive metastatic or locally recurrent breast cancer, in patients without prior treatment for metastatic disease. Treatment with pertuzumab should be stopped if disease progresses.	No subsidy	2400	600
Pomalidomide	Pomalidomide capsule (1 mg, 2 mg, 3 mg, 4 mg)	Pomalyst	Pomalidomide in combination with bortezomib or cyclophosphamide, plus dexamethasone, for patients with multiple myeloma who have received at least one prior therapy.	MAF	2000	600
Pomalidomide	Pomalidomide capsule (1 mg, 2 mg, 3 mg, 4 mg)	Pomalyst	Pomalidomide in combination with dexamethasone for patients with multiple myeloma who have received at least two prior therapies, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.	MAF	2000	600
Ponatinib	Ponatinib tablet (15 mg)	Iclusig	Treatment of chronic, accelerated, or blast phase chronic myeloid leukaemia (CML) in adults: • whose disease is resistant to imatinib or dasatinib or nilotinib, and who have the T315I mutation OR • whose disease is resistant to both nilotinib and dasatinib OR • whose disease is resistant to nilotinib or dasatinib and who are intolerant of/contraindicated to the other drug.	MAF	1200	600
Ponatinib	Ponatinib tablet (15 mg)	Iclusig	Treatment of adults with Philadelphia chromosome positive acute lymphoblastic leukaemia who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.	MAF	1200	600
Prednisolone	Prednisolone tablet (1 mg, 5 mg, 20 mg)	-	For cancer treatment.	SDL	200	600
Procarbazine	Procarbazine capsule (50 mg)	-	For cancer treatment.	SDL	800	600
Radium-223	Radium-223 solution for injection (1100 kBq/mL)	Xofigo	Treatment of patients with castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastatic disease.	No subsidy	1400	600
Ramucirumab	Ramucirumab concentrate for solution for infusion (100 mg/10 mL, 500 mg/50 mL)	Cyramza	Treatment of advanced unresectable hepatocellular carcinoma in patients with disease progression after 1 or more prior lines of systemic therapy, and who have serum alpha-fetoprotein (AFP) of ≥400 ng/ml, and have adequate liver function as assessed by the Child-Pugh scoring system.	No subsidy	1800	600
Ramucirumab	Ramucirumab concentrate for solution for infusion (100 mg/10 mL, 500 mg/50 mL)	Cyramza	Ramucirumab as monotherapy for patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma, with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.	No subsidy	1800	600
Ramucirumab	Ramucirumab concentrate for solution for infusion (100 mg/10 mL, 500 mg/50 mL)	Cyramza	Ramucirumab in combination with paclitaxel for patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma, with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.	No subsidy	1800	600
Ramucirumab	Ramucirumab concentrate for solution for infusion (100 mg/10 mL, 500 mg/50 mL)	Cyramza	Ramucirumab in combination with FOLFIRI for treating metastatic colorectal cancer that has progressed on first-line systemic therapy.	No subsidy	1800	600
Regorafenib	Regorafenib tablet (40 mg)	Stivarga	Treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumour (GIST) who have been previously treated with imatinib mesylate.	MAF	1800	600
Regorafenib	Regorafenib tablet (40 mg)	Stivarga	Treatment of advanced unresectable hepatocellular carcinoma in patients with disease progression after 1 or more prior lines of systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system.	MAF	1800	600
Regorafenib	Regorafenib tablet (40 mg)	Stivarga	Treatment of metastatic colorectal cancer that has been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and if RAS wild-type, an anti-EGFR therapy.	MAF	1800	600
Ribociclib	Ribociclib tablet (200 mg)	Kisqali	Ribociclib in combination with an aromatase inhibitor as initial endocrine-based therapy for HR positive, HER2 negative, advanced or metastatic breast cancer.	MAF	800	600
Ribociclib	Ribociclib tablet (200 mg)	Kisqali	Ribociclib in combination with fulvestrant for HR positive, HER2 negative, advanced or metastatic breast cancer in patients who have received prior endocrine therapy.	MAF	800	600
Rituximab	Rituximab biosimilar concentrate for infusion (100 mg/10 mL, 500 mg/50 mL)	Truxima	For cancer treatment.	SDL (Truxima)	1000	600
Rituximab	Rituximab concentrate for infusion (100 mg/10 mL, 500 mg/50 mL)	Mabthera Rixathon	For cancer treatment.	No subsidy	1000	600
Rituximab	Rituximab solution for subcutaneous injection (1400 mg/11.7 mL)	Mabthera	Rituximab (subcutaneous) in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), for the treatment of CD20+ diffuse large B-cell non-Hodgkin lymphoma.	No subsidy	1000	600
Rituximab	Rituximab solution for subcutaneous injection (1400 mg/11.7 mL)	Mabthera	Rituximab (subcutaneous) in combination with cyclophosphamide, vincristine, prednisone (CVP), for the treatment of previously untreated patients with stage III-IV follicular lymphoma.	No subsidy	1000	600
Rituximab	Rituximab solution for subcutaneous injection (1400 mg/11.7 mL)	Mabthera	Rituximab (subcutaneous) for maintenance treatment of patients with follicular lymphoma who have responded to induction therapy.	No subsidy	1000	600
Romidepsin	Romidepsin powder for solution for infusion (10 mg)	-	Treatment of peripheral T-cell lymphoma in adults who have received at least one prior therapy.	No subsidy	1800	600
Ruxolitinib	Ruxolitinib tablet (5 mg, 15 mg, 20 mg)	Jakavi	Treatment of patients with intermediate-2 or high-risk myelofibrosis with disease-related splenomegaly or symptoms.	MAF	2000	600
Siltuximab	Siltuximab powder for infusion (100 mg)	Sylvant	Treatment of adults with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.	No subsidy	3000	600
Sodium iodide [I-131]	Sodium iodide [I-131] capsule (37 to 6000 MBq)	-	For thyroid residue ablation after surgery of differentiated thyroid cancer, and treatment of iodine-accumulating metastases.	No subsidy	1600	600
Sorafenib	Sorafenib tablet (200 mg)	Nexavar	For cancer treatment.	SDL	1200	600
Sunitinib	Sunitinib capsule (12.5 mg, 25 mg, 37.5 mg, 50 mg)	Sutent	Treatment of patients with unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) who have had an inadequate response to imatinib mesylate treatment due to resistance or intolerance.	No subsidy	1600	600
Sunitinib	Sunitinib capsule (12.5 mg, 25 mg, 37.5 mg, 50 mg)	Sutent	Treatment of advanced renal cell carcinoma.	No subsidy	1600	600
Sunitinib	Sunitinib capsule (12.5 mg, 25 mg, 37.5 mg, 50 mg)	Sutent	Treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumors with disease progression.	No subsidy	1600	600
Talazoparib	Talazoparib capsule (0.25 mg, 1 mg)	Talzenna	Treatment of germline BRCA-mutated, HER2 negative, locally advanced or metastatic breast cancer in patients previously treated with chemotherapy.	No subsidy	1600	600
Tamoxifen	Tamoxifen tablet (20 mg)	-	For cancer treatment.	SDL	200	600
Tegafur + gimeracil+ oteracil	Tegafur + gimeracil + oteracil potassium capsule (20 mg/5.8 mg/19.6 mg, 25 mg/7.25 mg/24.5 mg)	TS-ONE	Treatment of locally advanced or metastatic adenocarcinoma of the pancreas.	No subsidy	200	600
Tegafur + gimeracil+ oteracil	Tegafur + gimeracil + oteracil potassium capsule (20 mg/5.8 mg/19.6 mg, 25 mg/7.25 mg/24.5 mg)	TS-ONE	Post-operative adjuvant treatment of locally advanced (stage II (excluding T1), IIIA or IIIB) gastric cancer.	No subsidy	200	600
Temozolomide	Temozolomide capsule (20 mg, 100 mg)	-	For cancer treatment.	SDL	800	600
Thalidomide	Thalidomide capsule (50 mg)	-	For cancer treatment.	SDL	400	600
Tioguanine	Tioguanine tablet (40 mg)	-	For cancer treatment.	SDL	1600	600
Trabectedin	Trabectedin powder for injection (1 mg)	Yondelis	Treatment of patients with advanced or metastatic soft tissue sarcoma, after failure of anthracyclines and ifosfamide (unless unsuitable).	No subsidy	1200	600
Trastuzumab	Trastuzumab biosimilar powder for IV infusion (440 mg)	Ogivri Herzuma	For cancer treatment.	SDL (Ogivri, Herzuma)	600	600
Trastuzumab	Trastuzumab powder for IV infusion (440 mg)	Herceptin Kanjinti Trazimera	For cancer treatment.	No subsidy	600	600
Trastuzumab	Trastuzumab solution for SC injection (600 mg/5 mL)	Herceptin	For cancer treatment.	No subsidy	600	600
Trastuzumab emtansine	Trastuzumab emtansine powder for concentrate for infusion solution (100 mg, 160 mg)	Kadcyla	Adjuvant treatment of HER2 positive early breast cancer in patients with residual invasive disease, after neoadjuvant treatment with trastuzumab and a taxane. Maximum 14 cycles.	No subsidy	2400	600
Trastuzumab emtansine	Trastuzumab emtansine powder for concentrate for infusion solution (100 mg, 160 mg)	Kadcyla	Treatment of HER2 positive, locally advanced, unresectable, or metastatic breast cancer in patients who have received prior treatment with trastuzumab and a taxane.	No subsidy	2400	600
Tretinoin	Tretinoin capsule (10 mg)	Vesanoid	For cancer treatment.	SDL	800	600
Trifluridine + tipiracil	Trifluridine + tipiracil tablet (15 mg/6.14 mg, 20 mg/8.19 mg)	Lonsurf	Treatment of metastatic colorectal cancer that has been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and if RAS wild-type, an anti-EGFR therapy.	No subsidy	1800	600
Trifluridine + tipiracil	Trifluridine + tipiracil tablet (15 mg/6.14 mg, 20 mg/8.19 mg)	Lonsurf	Treatment of patients with unresectable locally advanced or recurrent gastric or gastroesophageal junction adenocarcinoma after 2 or more prior systemic therapies.	No subsidy	1800	600
Triptorelin	Triptorelin injection (3.75 mg, 11.25 mg, 22.5 mg)	-	Treatment of locally advanced or metastatic, hormone-dependent prostate cancer.	No subsidy	200	600
Venetoclax	Venetoclax tablet (10 mg, 50 mg, 100 mg)	Venclexta	Monotherapy after completion of 6 cycles of obinutuzumab for patients with previously untreated chronic lymphocytic leukaemia (CLL) who are unsuitable for fludarabine-based therapy.	MAF	3000	600
Venetoclax	Venetoclax tablet (10 mg, 50 mg, 100 mg)	Venclexta	Venetoclax in combination with rituximab biosimilar for patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy. Maximum treatment duration of rituximab is 6 cycles and venetoclax is 24 months.	MAF	3000	600
Venetoclax	Venetoclax tablet (10 mg, 50 mg, 100 mg)	Venclexta	Treatment of newly diagnosed acute myeloid leukaemia (AML) in combination with a hypomethylating agent or low-dose cytarabine in patients who are ineligible for intensive chemotherapy.	No subsidy	3000	600
Venetoclax plus obinutuzumab	Venetoclax tablet (10 mg, 50 mg, 100 mg) Obinutuzumab concentrate for solution for infusion (1000 mg/40 mL)	Venclexta Gazyva	Venetoclax in combination with obinutuzumab for patients with previously untreated chronic lymphocytic leukemia (CLL) who are unsuitable for fludarabine-based therapy. Maximum treatment duration of obinutuzumab is 6 cycles and venetoclax is 12 months.	MAF	5400	600
Vinblastine sulfate	Vinblastine sulfate vial (10 mg)	-	For cancer treatment.	SDL	200	600
Vincristine sulfate	Vincristine sulfate vial (1 mg)	-	For cancer treatment.	SDL	200	600
Vinflunine	Vinflunine concentrate for solution for infusion (50 mg/2 mL, 100 mg/4 mL, 250 mg/10 mL)	Javlor	Treatment of patients with locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy.	No subsidy	1800	600
Vinorelbine	Vinorelbine capsule (20 mg, 30 mg)	-	(Undergoing Evaluation)	(Undergoing Evaluation)	(Undergoing Evaluation)	(Undergoing Evaluation)
Vinorelbine	Vinorelbine injection (50 mg/5 mL)	-	For cancer treatment.	SDL	400	600